Medipost said Wednesday that it has acquired patents in Mexico on its core production technology of Cartistem.
Cartistem is the world’s first cord blood-derived mesenchymal stem cell treatment, which won the marketing license from the Ministry of Food and Drug Safety in January 2012.
The patent, named “TSP-1, TSP-2, IL-17BR and HB-EGF associated with stem cell activities and applications thereof,” relates to a technology for preventing or treating cartilage damage, degeneration, deficiency, and degenerative arthritis. The patent also includes cord blood-derived mesenchymal stem cells expressing TSP-2 protein composition.
MediPost acquired 10 domestic and foreign patents related to stem cell treatment drugs last year and is actively involved in research and development (R&D) to secure future-oriented core technologies, the company said.
<© Korea Biomedical Review, All rights reserved.>